XO as a Screening Test of Cognitive Impairment in Multiple Sclerosis
Evaluation of a New Screening Test of Cognitive Impairment Among Multiple Sclerosis Patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- questionnaire completion
What it measured
Main measures
Score of XO test
Day 0
Other measures (4)
Score of anxiety
Day 0
Mood and sleepScore of depression
Day 0
Mood and sleepScore of asthenia
Day 0
FatigueScore of pain
Day 0
Pain
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
* Multiple sclerosis patients included must : * Be men or women aged 18 or more * Be diagnosed Multiple Sclerosis (MacDonald criteria, 2017) * No relapse in the previous month * Be mother-tongue French, or speaking French fluently * Be covered by French social security Healthy controls included must : * Be men or women aged 18 or more * Suffer from no pathology that might be incompatible with the study
Exclusion criteria
* - Patients or controls declining participation to the study, or legally protected, pregnant or breastfeeding women * Patients suffering from another neurological disease, psychiatric disorder, or developmental abnormalities that were diagnosed before multiple sclerosis * Patients with cranial trauma, relapse that ended less than 1 month before, or depression less than 3 months * Patients with severe motor or visual disabilities
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Even at the disease onset, about 70% of patients with multiple sclerosis (MS) suffer from cognitive impairment that impacts quality of life. Currently, some speed processing tests are used, such as SDMT ( symbol digit modalities test ), CSCT (information treatment speed evaluation) and WAIS-IV (Weschler Adult Intelligence Scale ). Their inconvenient are the improvement of scores in test-retest, and some difficulties doing the tests due to motor or visual impairment that might be reported. The XO test is fast, cheap and easy to use during medical consult by neurologists. It seems to be correlated to results of speed processing tests, and probably to some executive functions tests too. Asthenia, anxiety, depression and pain are likely to have a negative influence on tests results. Screening every patients with a short test aims to detect patients with cognitive impairment earlier. After a positive screening test, and to better characterize cognitive impairment, they will undergo a neuropsychological test battery. Depending on the alteration, adapted workstation, financial support, technical and human helps will be implemented in order to improve the daily-living of patients. This study aims to approve the XO as a screening test of cognitive impairment in MS patients. We will study the relationship between XO test, and SDMT, CSCT, WAIS-IV, and also with questionnaires about pain, asthenia (FSS, Fatigue Severity Scale), anxiety and depression (HAD, Hospital Anxiety and Depression ). The XO test will be standardized using a healthy population.
Loading reviews and guidelines…
History
Started
Jul 2019
Main results due
Sept 2020
Finished
Oct 2020